Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Roaring Kitty Surfaces While Large Caps & AI Stocks Move Higher This Week – $ADT $AMZN $AAPL $GME $MSFT $NVDA $XBI Rise!

By John F. Heerdink, Jr.
Quote of the Day: “There are no shortcuts in evolution.” – Louis D. Brandeis

Happy Saturday!

I hope that you had a wonderful week & that it proved to be profitable one as well. As for me, I spent the week traveling to and from Nashville and Boston meeting with a number of CEO’s and investors at our sister firm Tribe Public (www.tribepublic.com)  CEO Presentation and Q&A Luncheon and Dinner Events and continued to gain great insights across the board via this direct corporate access platform.  I will be back to Nashville to co-host with Panna Sharma of Lantern Pharma (LTRN) on Wednesday, June 12. Please let me know if you would like to join either the luncheon event or the dinner event that day. 

As for the broad stock market this week, large equities overall trended higher, while the small came under pressure. Interestingly, one of the stories of the week came from memes stock world and particularly from GamesStop (GME, $28.22, +21.95% ver the last 5-days) and Keith Gill’s righteous return to YouTube. However, on Friday GameStop posted an adjusted loss of $.12/sh missing estimates & Net sales fell 29% to $882M.

This week’s US macroeconomic schedule offered a number of reports that keep the inflation story alive. On Monday, the Final May S&P Global US Manufacturing PMI report came in higher at 51.3 & the May ISM Manufacturing Index report that clocked in lower than expected at 48.7% showing significant contraction. The April Construction Spending report came in lower than expected at -.1%. On Tuesday, the April Factory Orders report came in slightly higher than expected at .7% & the April JOLTS report came in lower at 8.059M. On Wednesday, the Weekly MBA Mortgage Applications Index report confirmed a 5.2% drop, while the May ADP Employment Change report came in lower at 152k. The Final May S&P Global US Services PMI report came in higher at 54.8, while the May ISM Non-Manufacturing Index report also increased  to 53.8%. On Thursday, the Weekly Initial Claims report clocked higher than expected at 229k, while the Weekly Continuing Claims ticked higher to 1.792M as the jobs market may just be showing some cracks. The Q1 Productivity clocked in below expectations at .2%, while Q1 Unit Labor Costs came in lower than expected at 4.0%. The April Trade Balance report came in at -$74.6. On Friday, the May Nonfarm Payrolls report clocked in at 272k & May Nonfarm Private Payrolls was at 229k. The average May Hourly Earnings report came in at .4% & the May Unemployment Rate was 4% and the May Average Workweek was at 34.3. The April Wholesale Inventories report was at .1%.

Over the course of the week, the yield curve pulled back this week with the 10-yr note yield closing down 8bps at 4.43% & the 2-yr note yield moving down by 2bps to 4.87%.

Oil prices closed at $75.25/bbl, -.7% now up 5% YTD & the U.S. Dollar Index moved lower this week from 104.63 to 104.94.

The CBOE Volatility Index (^VIX) fell again over the course of the week down -6.79% to close at $12.22.

At the end of the week, the Dow 30 closed at 38,798.99 (+.3%) this week and is up +2.9% YTD. 

The S&P 500 closed at 5,346.99 (+1.3%) and is now up 12.1% YTD.

The Nasdaq closed at 16,735.02 (+2.4%) and is now up 14.1% YTD. The Magnificent 7 closed across the board as follows over the last 5-days: Alphabet (GOOG) closing at $175.96, +1.14%, Amazon (AMZN) closing at $184.30, +4.45%, Apple (AAPL) at $196.89, +2.41%, Meta Platforms (META) closing at $492.96, +5.60%, Microsoft (MSFT) closing at $423.85, +2.10%, NVIDIA (NVDA) closing at $1,208.88, +10.27%, & Tesla (TSLA) closing at $177.48, -.34%. 

The small caps on the Russell 2000 closed at 2,026.55 (-2.1%) for the week & is now up 0.0% YTD, while the MicroCaps closed higher this week as the iShares Micro-Cap ETF (IWC) closed at $113.95, -3.02% over the week.

Bank stocks on The SPDR S&P Regional Banking ETF (KRE) moved down to close at $47.21, -3.38% over the last 5-days & the SPDR S&P Bank ETF (KBE) moved down over the last 5-days to close at $45.03, -2.60% this week.  

Overall, The Nasdaq Biotechnology ETF (IBB) closed at $136.72, +2.12% & the SPDR S&P Biotech ETF (XBI) closed at $91.39, +2.54% over the last 5-days. The iShares U.S. Healthcare ETF (IYH) closed at $61.31, +1.79% over the last 5-days. 

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $43.80, +3.18% over the last 5-days.

From the world of cryptocurrency, Bitcoin (BTC) moved from $67,582.92 to 69,378.74 over the course of the last 5-days at the time of the completion of this message.

Gold prices closed at $2,297/.oz down from $2,330/.oz over the last 5-days. Silver prices closed at $29.20/.oz down from $30.42/oz. 

VP Watchlist Updates

Eupraxia Pharmaceuticals (EPRX, $2.68) is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods.

Eupraxia recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to osteoarthritis of the knee. The trial met its primary endpoint and three of the four secondary endpoints. Eupraxia has expanded the EP-104 platform into gastrointestinal disease with the Phase 1b/2a RESOLVE trial for treating EoE. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

On June 5, Eupraxia announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology (“EULAR”) European Congress of Rheumatology 2024 (the “Meeting”). The EULAR Meeting is being held in Vienna, Austria from June 12-15, 2024.

On May 23, Eupraxia announced that regulators in Australia and Canada have cleared the Company’s request to expand its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”). For further details about Eupraxia, please visit the Company’s website at: www.eupraxiapharma.com.

Modular Medical, Inc. (NASDAQ: MODD, $1.585, -2.76% over the last 5-days), is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
On March 6, Modular Medical’s CEO Jeb Besser presented at Tribe Public’s Webinar Presentation and Q&A Event titled “Revolutionizing Diabetes Care.”  You may view the event video now to learn more by clicking this link.

On June 3, Modular Medical announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

On Feb. 21, Modular Medical announced the closing of its previously announced underwritten public offering (the “offering”) of 9,090,910 shares of its common stock, led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical’s Chief Executive Officer, and Morgan Frank, a member of the Company’s board of directors, and other existing institutional investors. Each share of common stock was sold at a price to the public of $1.10 per share. The gross proceeds to Modular Medical from this offering were approximately $10 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures. In addition, Modular Medical has granted the underwriters a 30-day option to purchase up to an additional 1,321,989 shares of common stock to cover over-allotments, if any.Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.

On Jan. 24, Modular Medical announced the issuance of U.S. Patent 11,817,197 B2 for the stream-lined pairing of a pump to a mobile device. Paul DiPerna, Chairman and CTO of Modular Medical, commented, “The issuance of this patent is just another step in our mission to use technology to rethink and simplify the adoption of and ability to live with pump technology for patients and caregivers. To address cybersecurity risks and the complexity of pairing multiple devices to talk between a phone and a pump, we added Near-Field Communication (NFC), whereby, just by bringing the phone close to our pump will create a secure connection making it much easier to develop, test and maintain. This patent protects our technology addressing pairing, and, most importantly, the downloading of patient data to allow clinicians to easier upload and review the patients data. The patient’s phone is not required, and a clinician can simply tap the pump to the phone or tablet to pull the data using Bluetooth from patient pumps. In a high-volume practice, such as a busy certified pump trainer’s office, the ability to pull data from several patients quickly is critical. Our patented technology addresses the ability to do this without the tedious step of powering on and pairing with a myriad of new Bluetooth devices. It also simplifies moving the configuration to a new reusable controller, when needed, without using an intermediate device.” Jeb Besser, Modular Medical’s CEO, commented, “Our family of patents, which includes both issued patents and pending applications, around our pump is an important part of our strategic value and market positioning, and we look forward to announcing further patent issuances in the future.”
On Jan. 19, Modular Medical announced the premarket submission of its MODD1 next-generation insulin pump to the FDA for 510(k) clearance. “This is an exciting milestone for the Company, as we seek to change the diabetes market. Almost 30 years after the introduction of the first insulin pump, more than three quarters of those who could benefit from wearing a pump do not wear one. It is our belief that our simplified design will encourage many “almost-pumpers” to adopt technology to aid in their diabetes management, without the complexity and expense required by many of the current solutions,” said Paul DiPerna, Chairman and CTO of Modular Medical.
On Dec. 21, Modular Medical announced a collaboration agreement with Glooko, Inc., a global leader specializing in connected care and remote patient monitoring for diabetes. Integrating with Glooko will allow clinicians and patients to easily review insulin dosing data from the MODD1 pump, when commercially available. In addition, through Glooko’s platform, Dexcom CGMS users will be able to view their glucose levels in the same accessible format in conjunction with their pump data. Glooko’s platform has a broad installed base, which has been deployed in over 30 countries and 8,000 clinical locations. Jeb Besser, CEO of Modular Medical stated, “We are extremely pleased to add the Glooko technology platform to our diabetes care system making it even easier and more cost effective for us to provide this important capability to our clinical and patient base. Glooko’s mission to improve health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform fits perfectly with our vision of providing an easy to use, affordable delivery technology to give more patients access to better care.”

Lantern (LTRN) closed at $5.58, -8.07%, but jumped +18.62%and is up +30.37% YTD).  Lantern is an Artificial Intelligence (AI) firm that is transforming the cost, pace, and timeline of oncology drug discovery and development and specifically is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs.

  • On May 9, Lantern announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024. Lantern highlighted the following progress:

    • Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024.
    • Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% of all lung cancer cases occur in never-smokers with NSCLC; Harmonic™ continues patient enrollment in the US.
    • Phase 1 clinical trials for both synthetic lethal drug-candidates, LP-184 and LP-284, continue to advance with no dose-limiting toxicities observed in any of the patient cohorts enrolled and dosed to date.
    • The combined annual global sales market potential for LP-184 and LP-284 across multiple cancer indications is estimated to be over $12 billion USD.
    • Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma focused on CNS and brain cancers with STAR-001, advanced with the filing of a clinical trial protocol for the Phase 1B dose optimization and expansion cohort in recurrent IDH wild-type high grade gliomas.
    • Advanced AI-powered module for streamlining and guiding differentiated ADC development, which will be instrumental in the next-generation of drug candidates for Lantern Pharma and its collaborators.
    • Established an AI driven collaboration with Oregon Therapeutics where the RADR® platform will be leveraged to sharpen, expand and derisk future clinical development strategies for a novel, first-in-class inhibitor of cancer metabolism.
    • Approximately $38.4 million in cash, cash equivalents, and marketable securities as of March 31, 2024.

    On May 6, Lantern announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI)(1) inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its proprietary RADR® AI platform to uncover biomarkers and efficacy-associated signatures of XCE853 across solid tumors that can aid in precision development. Collaborative efforts are expected to identify biomarker signatures that can be used to stratify tumors most responsive to XCE853 and guide potential future clinical development and patient selection. Oregon Therapeutics is developing XCE853 in various cancer indications, including drug-resistant ovarian and pancreatic cancer, certain hematological cancers and several pediatric cancers including CNS cancers. Lantern highlighted the following:

    • XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development.
    • The AI-enabled collaboration aims to refine and expand the positioning of XCE853, a novel protein disulfide isomerase (PDI) inhibitor, in new and targeted oncology indications, including for drug-resistant tumors.
    • The collaboration is leveraging RADR®’s AI-based capabilities, including 200+ machine learning (ML) algorithms and foundational models for oncology drug development to uncover biomarkers and molecular correlates of efficacy and define potential combination regimens to sharpen XCE853’s drug development strategy.
    • Lantern Pharma is receiving equal IP co-ownership and drug development rights in newly discovered biomarkers, novel indications, and use for new pharmacological strategies for XCE853.

Watch “How AI Has Lit A Revolution In Healthcare, Medicine, & Human Longevity”  on The Tribe Public Channel as Panna Sharma CEO Lantern Pharma was interviewed on Feb. 29.

Shares of Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, closed at  $2.65, +11.81% over the last 5-days and is up 50.57% YTD. Click to watch a brief video on Indaptus Therapeutics’ Decoy20 Cancer Treatment Approach.

On June 4, Indaptus announced that it will present a poster titled, “Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors,” at the American Society of Clinical Oncology annual meeting on June 1, 2024, in Chicago.

On May 22, Indaptus announced the successful advancement of its Phase 1 trial for Decoy20, an investigational novel package of broad immune agonists for cancer immunotherapy that has first-in-class potential across a diverse range of cancers including liver, pancreatic, colorectal and non-small cell lung. Following review by a Safety Review Committee (SRC) of the company’s initial clinical data, which will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), the Company has successfully dosed the first patient in the multi-dose portion of the trial with Decoy20. The primary goal of this stage of the trial is to determine the safety of Decoy20 when administered multiple times to the same patient, and to begin to examine efficacy across multiple types of cancer. Decoy20 is composed of attenuated and killed, intact, non-pathogenic Gram-negative bacteria which are designed to act as a “decoy,” tricking the body into activating a broad antitumor response from both its innate and adaptive immune systems. In preclinical studies, the treatment has been shown to activate specialized immune receptors called TLRs, that facilitate a potent defense against tumors, without inducing excessive toxicity. The product candidate is designed to induce a strong and broad pulse of immune activation, followed by rapid clearance from the body.“Current immunotherapies usually target a few immune system pathways and have low cure rates in advanced cancers. Indaptus is investigating an incredibly exciting and differentiated approach to fighting cancerous tumors that deviates from a focus on targeted therapies in the field. The advancement of this trial is a significant milestone that builds on strong evidence that Decoy20 successfully and broadly activates potent tumor-fighting cytokines and chemokines in both the innate and adaptive immune systems, and was administered systemically without intolerable adverse events,”stated Roger Waltzman, MD, Chief Medical Officer of Indaptus.

On May 8, Indaptus announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. 


Jeffrey Meckler, CEO, Indaptus Therapuetics, Inc. (NASDAQ: INDP)

Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, “We continue to make steady progress in our clinical development plans and are receiving regular validation for results reported to date, both through a presentation in April at the American Association for Cancer Research (AACR) annual meeting, and the acceptance of further data to be presented in a poster at the American Society of Clinical Oncology (ASCO) annual meeting, which is considered among the top annual oncology conferences. We are encouraged by the results we have reported, along with the early results we are seeing as we advance our trial, and believe they are indicative of the potential for Decoy20, and indeed our platform as a whole. We look forward to reporting more about our progress as it develops.”

On April 11, Indaptus announced it was proud to unveil its poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday, April 10th. The poster details mechanism of action data that demonstrates the Company’s Decoy platform successfully induces, matures or activates multiple immune cell types involved in anti-tumor responses. The latest findings significantly enhance the Company’s understanding of its “Decoy” platform technology, which uses killed, non-pathogenic bacteria engineered to activate the immune system to attack tumors. The study highlights the platform’s effectiveness in engaging key innate and adaptive immune cells, including, natural killer cells, natural killer T cells, dendritic cells, CD4+, and CD8+ T cells. In some settings, the platform also produced additive or synergistic activity in combination with IL-2, an approved cancer drug. Additionally, the data reveal that the Decoy platform may not only boost the immune system’s ability to recognize and kill tumor cells, but potentially also overcome a mechanism that suppresses the immune response. The results suggest that the Company’s Decoy bacteria can both directly and indirectly prime the immune system to more effectively fight cancer. Jeffrey Meckler, Indaptus’ Chief Executive Officer, added, “We are encouraged by the promising results observed in our preclinical studies and our ongoing Phase 1 clinical trial. The recognition and validation from prestigious organizations such as the AACR, coupled with the support and insights we are receiving from medical experts, partners and investors at the conference, inspire us to continue advancing our technology and demonstrating its significant therapeutic potential for the treatment of solid tumors.” The full poster can be accessed on the Indaptus Therapeutics website by clicking here.

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors. This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20’s potential as a multifaceted immunotherapy.”

The Company recently initiated the multi-dose cohort of its Phase 1 clinical trial in solid tumors. Learn more by clicking here!

Indaptus CEO presented in an open Q&A on Tribe Public’s Webinar titled, “Fully Engaging The Human Immune System To Cure Disease” on Wednesday, March 20, 2024. You can now watch the event video at the Tribe Public YouTube Channel at this link

Learn more about Indaptus Therapeutics (NASDAQ: INDP) at the VP Watchlist page by clicking here.


Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $7.35, +3.38% over the last 5-days and +7.77% YTD.

On April 25, ADT report their Q1 earnings results highlighting the following:  

  • Total revenue of $1.2 billion with end-of-period recurring monthly revenue (RMR) up 3% to $353 million ($4.2 billion on an annualized basis)
  • Consumer and Small Business (CSB) revenue of $1.2 billion, up 5% and segment Adjusted EBITDA of $638 million, up 8%
  • Strong customer retention with gross revenue attrition of 13.1%
  • GAAP income from continuing operations of $92 million, or $0.10 per diluted share, up $218 millionAdjusted income from continuing operations of $151 million, or $0.16 per diluted share, up $56 million

On March 6, ADT announced the pricing of a secondary public offering of 65,000,000 shares of the Company’s common stock held by certain entities managed by affiliates of Apollo Global Management, Inc. (the “Selling Stockholders”) at a price to the public of $6.50 per share. The offering is expected to close on March 11, 2024, subject to satisfaction of customary conditions.The underwriters will have a 30-day option to purchase up to an additional 9,750,000 shares of common stock from the Selling Stockholders. The Company is not selling any shares and will not receive any proceeds from the offering. In addition, ADT has authorized the concurrent purchase from the underwriters of 15,000,000 shares of common stock as part of the secondary public offering (the “Share Repurchase”) subject to the completion of the offering. The Share Repurchase is part of the Company’s existing $350 million share repurchase program. The underwriters will not receive any underwriting fees for the shares being repurchased by the Company. Morgan Stanley, Barclays, Apollo Global Securities and RBC Capital Markets are acting as book-running managers for the offering. BNP PARIBAS, Deutsche Bank Securities, Mizuho, Goldman Sachs & Co. LLC, MUFG, BMO Capital Markets, BTIG and Raymond James are acting as joint book-runners for the offering. Berenberg, Fifth Third Securities, Academy Securities, Bancroft Capital and Siebert Williams Shank are acting as co-managers for the offering.

Shares of Seanergy Maritime Holdings Corp. (SHIP), the only pure-play Capesize ship-owner publicly listed in the U.S. closed at $11.89, -1.57% over last 5-days and up +51.85% YTD. Seaenergy is a prominent pure-play Capesize ship-owner publicly listed in the U.S. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. The Company’s operating fleet consists of 17 vessels (1 Newcastlemax and 16 Capesize) with an average age of approximately 13.2 years and an aggregate cargo carrying capacity of approximately 3,054,820 dwt. Upon delivery of the two Capesize vessels, the Company’s operating fleet will consist of 19 vessels (1 Newcastlemax and 18 Capesize) with an aggregate cargo carrying capacity of approximately 3,417,608 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”.

On May 15, Seaenergy announced its financial results for the first quarter ended March 31, 2024. The Company also declared a quarterly cash dividend of $0.025 per common share and a special cash dividend of $0.125 per common share for the first quarter of 2024. For the quarter ended March 31, 2024, the Company generated Net Revenues of $38.3 million, compared to $18.0 million in the first quarter of 2023. Net Income and Adjusted Net Income for the quarter were $10.2 million and $11.6 million, respectively, compared to Net Loss of $4.2 million and Adjusted Net Loss of $0.4 million in the first quarter of 2023. EBITDA and Adjusted EBITDA for the quarter were $21.6 million and $23.2 million, respectively, compared to $8.2 million and $3.9 million, respectively, for the same period of 2023. The daily Time Charter Equivalent (“TCE”2) of the fleet for the first quarter of 2024 was $24,073, compared to $11,005 in the same period of 2023. Cash and cash-equivalents and restricted cash, as of March 31, 2024, stood at $2


On Jan, 23, NAYA Biosciences Inc. (“NAYA”), a company which has recently signed a definitive merger agreement with INVO Bioscience (INVO, $.78, -9.30% over the last 5-days) to establish an expanded, publicly-traded life science company dedicated to increasing patient access to breakthrough treatments in oncology, regenerative medicine, and fertility, today announced that it has entered into a binding letter of intent to acquire Florida Biotechnologies, Inc. a gene therapy company focusing on the treatment of mitochondrial diseases.announced that it has entered into a binding letter of intent to acquire Florida Biotechnologies, Inc. a gene therapy company focusing on the treatment of mitochondrial diseases. “We are delighted to contribute to the emergence of a strong biotech ecosystem leveraging Florida’s academic medical excellence,” commented Florida Biotechnologies cofounder Dr. Peter Kash. “The NAYA leadership team brings an agile entrepreneurial platform, broad development and commercialization experience, and access to public capital, which will unlock the potential of our promising AAV gene therapy platform for mitochondrial genetic diseases. As it expands its clinical pipeline to additional regenerative medicine as well as oncology and fertility programs, NAYA is poised to build a world-class Miami-based biopharmaceutical company.” “We are impressed by the initial safety and efficacy of the AAV gene therapy developed by Florida Biotechnologies and the University of Miami for the treatment of LHON, a rare and debilitating genetic disease with no currently approved therapeutic regimen,” commented NAYA Chairman & CEO Dr. Daniel Teper. “NAYA is committed to accelerating clinical development and Early Patient Access to this breakthrough therapy, which has the potential to achieve curative results in patients with progressive vision loss and blindness.”

On May. 15, INVO Bioscience, Inc. announced financial results for the first quarter of 2024 and provided a business update. Revenue was $1,576,286, an increase of 353% compared to $348,025.

Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again as we move forward!

Investing & Inspiration

  1. “There are no shortcuts in evolution.” – Louis D. Brandeis
  2. “A friend may well be reckoned the masterpiece of nature.” –  Ralph Waldo Emerson
  3. “Nature uses as little as possible of anything.” – Johannes Kepler
  4. “Every new beginning comes from some other beginning’s end.” – Seneca
  5. “Nothing ever becomes real till it is experienced.” – John Keats
  6. “Nobody who ever gave his best regretted it.” – George Halas
  7. “Honest disagreement is often a good sign of progress.” – Mahatma Gandhi
  8. “A leader is one who knows the way, goes the way, and shows the way.” – John C. Maxwell
  9. “They always say time changes things, but you actually have to change them yourself.” – Andy Warhol
  10. “The secret of happiness is something to do.” – John Burroughs
  11. “The world of reality has its limits; the world of imagination is boundless.”
  12. “You begin with the possibilities of the material.” – Robert Rauschenberg
  13. “The only Zen you can find on the tops of mountains is the Zen you bring up there.” – Robert M. Pirsig
  14. “Leadership is the capacity to translate vision into reality.” – Warren Bennis
  15. “A man should always consider how much he has more than he wants.” – Joseph Addison
  16. “Happiness is good health and a bad memory.” –  Ingrid Bergman
  17. “We pass through this world but once.” – Stephen Jay Gould
  18. “Christmas waves a magic wand over this world, and behold, everything is softer and more beautiful.” – Norman Vincent Peale
  19. “Nothing can have value without being an object of utility.” – Karl Marx
  20. “Always turn a negative situation into a positive situation.” – Michael Jordan
  21. “Courage is found in unlikely places.” – J. R. R. Tolkien
  22. “One that would have the fruit must climb the tree.” – Thomas Fuller
  23. “Someone is sitting in the shade today because someone planted a tree a long time ago.” – Warren Buffett
  24. “We relish news of our heroes, forgetting that we are extraordinary to somebody too.” – Helen Hayes
  25. “A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing.” – George Bernard Shaw
  26. “Everything in the world may be endured except continual prosperity.”  – Johann Wolfgang von Goethe
  27. “Nine-tenths of wisdom is being wise in time.” – Theodore Roosevelt
  28. “Time is money.” – Benjamin Franklin
  29. “Change before you have to.” – Jack Welch
  30. “Our deeds determine us, as much as we determine our deeds.” – George Eliot
  31. “The Universe is under no obligation to make sense to you.” – Neil deGrasse Tyson
  32. “Care and diligence bring luck.” – Thomas Fuller
  33. “Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
  34. “A man who is a master of patience is master of everything else.” – George Savile
  35. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  36. “Endurance is nobler than strength, and patience than beauty.” – John Ruskin
  37. “Act as if what you do makes a difference. It does.” – William James
  38. “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” –  Marcel Proust
  39. “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
  40. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
  41. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
  42. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
  43. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  44. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  45. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  46. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  47. “Action is the foundational key to all success.” – Pablo Picasso
  48. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  49. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  50. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  51. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  52. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  53. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  54. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  55. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  56. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  57. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  58. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  59. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  60. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  61. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  62. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  63. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  64. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  65. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  66. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  67. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  68. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  69. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  70. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  71. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  72. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
  73. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  74. “I want to put a ding in the universe.” – Steve Jobs

  75. “Research is creating new knowledge.” – Neil Armstrong

  76. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  77. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  78. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
  79. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  80. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
  81. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  82. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  83. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
  84. “The best way out is always through.” – Robert Frost

  85. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
  86. “Without labor nothing prospers.” – Sophocles

  87. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
  88. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  89. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  90. “He who is brave is free.” – Lucius Annaeus Seneca
  91. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  92. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  93. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  94. “He who knows that enough is enough will always have enough.” – Lao Tzu

  95. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
  96. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  97. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  98. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  99. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  100. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  101. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  102. “Success is dependent on effort.” – Sophocles
  103. “Nobody who ever gave his best regretted it.” – George Halas
  104. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  105. “And when I breathed, my breath was lightning.” – Black Elk
  106. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  107. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  108. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  109. “We are an impossibility in an impossible universe.” – Ray Bradbury
  110. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  111. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  112. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  113. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  114. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  115. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  116. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  117. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  118. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  119. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  120. “There is more to life than increasing its speed.” – Mahatma Gandhi
  121. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  122. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  123. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  124. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  125. “Life is too short for long-term grudges.” – Elon Musk
  126. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  127. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  128. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  129. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  130. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  131. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  132. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  133. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  134. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  135. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  136. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  137. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  138. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  139. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  140. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  141. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  142. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  143. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  144. “Delete the negative; accentuate the positive!” – Donna Karan
  145. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  146. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  147. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  148. “Everything has beauty, but not everyone sees it.” – Confucius
  149. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  150. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  151. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  152. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  153. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  154. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  155. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  156. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  157. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  158. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  159. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  160. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  161. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  162. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  163. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  164. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  165. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  166. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  167. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  168. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  169. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  170. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  171. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  172. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  173. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  174. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  175. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  176. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  177. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  178. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  179. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  180. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  181. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  182. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  183. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  184. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  185. “The secret of getting ahead is getting started.” – Mark Twain
  186. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe